Last reviewed · How we verify
VAL-083
At a glance
| Generic name | VAL-083 |
|---|---|
| Also known as | Dianhydrogalactitol |
| Sponsor | Kintara Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (PHASE2, PHASE3)
- Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression (PHASE2)
- VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM (PHASE3)
- Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting (PHASE2)
- Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma (PHASE1, PHASE2)
- Expanded Access to VAL-083
- A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VAL-083 CI brief — competitive landscape report
- VAL-083 updates RSS · CI watch RSS
- Kintara Therapeutics, Inc. portfolio CI